Views: 60 Author: Unibest Industrial Publish Time: 2024-10-08 Origin: Site
Query Drug:Elacestrant
Query Time:2024-10-08 16:20:43
*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Unibest does NOT accept legal responsibility for ANY medical actions taken based on this information. ALWAYS consult with your doctor for medical advice. In addition, this product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Elacestrant is used to treat advanced hormone-related breast cancer in postmenopausal women and adult men when cancer has progressed or has spread to other parts of the body (metastatic) after other treatments have failed.
Your doctor will make sure you have the correct tumor type to be treated with elacestrant.
Elacestrant may also be used for purposes not listed in this medication guide.
Breast Neoplasms
Source MEDRT
Source MEDRT
Source: MEDRT
Source: MEDRT
[Last update] 2024-08-09
Elacestrant's Innovator is STEMLINE THERAPEUTICS INC
The unique dosage forms from the innovator include:1. TABLET;ORAL.
Index | Route | Brand Name | Labeler | Approval Date | Dosage |
---|---|---|---|---|---|
1 | TABLET;ORAL | ORSERDU | STEMLINE THERAPEUTICS INC | Jan 27, 2023 | EQ 345MG BASE |
2 | TABLET;ORAL | ORSERDU | STEMLINE THERAPEUTICS INC | Jan 27, 2023 | EQ 86MG BASE |
This drug still has 8 effective patents.
Patent Number | Submission Date | Expiration Date | Drug Substance Patent? | Drug Product Patent? |
---|---|---|---|---|
10071066 | Feb 24, 2023 | Oct 10, 2034 | ||
8399520 | Feb 24, 2023 | Dec 25, 2024 | Y | Y |
10745343 | Feb 24, 2023 | Jan 5, 2038 | ||
10420734 | Mar 10, 2023 | Oct 10, 2034 | ||
7612114 | Mar 10, 2023 | Aug 18, 2026 | Y | Y |
10385008 | Mar 10, 2023 | Jan 5, 2038 | Y | Y |
11779552 | Nov 6, 2023 | Oct 10, 2034 | ||
11819480 | Dec 21, 2023 | Nov 29, 2036 |
The innovator STEMLINE THERAPEUTICS INC's portolio contains products with the following 1 API(s): ELACESTRANT DIHYDROCHLORIDE
The above products are related to 1 diseases: Breast Neoplasms